Vitaspring Biomedical annual gross margin
2018
2019
2020
2021
2022
Vitaspring Biomedical's gross margin was 36.84% for fiscal 2022.
View full Vitaspring Biomedical company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2022 | 2022-01-31 | 36.84% | −8.36 pp |
| 2021 | 2021-01-31 | 45.21% | +34.01 pp |
| 2020 | 2020-01-31 | 11.20% | −68.65 pp |
| 2019 | 2019-01-31 | 79.85% | +9.97 pp |
| 2018 | 2018-01-31 | 69.88% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q1 2023 | 2022-04-30 | 38.12% | −6.80 pp |
| Q4 2022 | 2022-01-31 | 42.05% | −3.16 pp |
| Q3 2022 | 2021-10-31 | 10.00% | +306.00 pp |
| Q2 2022 | 2021-07-31 | 24.54% | −64.47 pp |
| Q1 2022 | 2021-04-30 | 44.92% | −42.55 pp |
| Q4 2021 | 2021-01-31 | 45.21% | −42.74 pp |
| Q4 2020 | 2020-01-31 | −296.00% | −381.33 pp |
| Q2 2020 | 2019-07-31 | 89.01% | +9.61 pp |
| Q1 2020 | 2019-04-30 | 87.47% | +9.31 pp |
| Q4 2019 | 2019-01-31 | 87.95% | +11.46 pp |
| Q3 2019 | 2018-10-31 | 85.33% | −0.59 pp |
| Q2 2019 | 2018-07-31 | 79.40% | +40.32 pp |
| Q1 2019 | 2018-04-30 | 78.16% | −6.02 pp |
| Q4 2018 | 2018-01-31 | 76.48% | — |
| Q3 2018 | 2017-10-31 | 85.92% | — |
| Q2 2018 | 2017-07-31 | 39.08% | — |
| Q1 2018 | 2017-04-30 | 84.18% | — |
Across the available reported history, Vitaspring Biomedical's gross margin decreased from 45.21% to 36.84%, a change of −8.36 percentage points. The latest reported quarter, Q1 2023, shows 38.12%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vitaspring Biomedical filings at SEC.gov ↗